Milhem talks about the mechanism of action, delivery methodology and ongoing trials with RP1

welcome to OncLive on the air®! I’m your host today, Jessica Hergert.

OncLive on the air® is a podcast by Live®, which provides oncology professionals with the resources and information they need to provide the best patient care. In digital and printed format, Live® covers all aspects of oncology practice, from new technologies to therapeutic advances to important regulatory decisions.

In today’s episode, sponsored by Replimune, we had the pleasure of speaking with Mohammed Milhem, MBBS, Holden Chair in Experimental Therapeutics, Associate Director of Clinical Research and Director of the Melanoma Program, Holden Comprehensive Cancer Center, director of the division of hematology, oncology, and blood and bone marrow transplantation, and clinical professor at the University of Iowa Hospitals and Clinics, to discuss the unique elements of oncolytic vaccines in oncology and ongoing research on vusolimogeneoderparepvec (RP1) in melanoma and other solid tumors.

Oncolytic vaccines, such as RP1, have generated considerable excitement across oncology, Milhem explained, citing ease of administration, mild toxicity profile and rapid responses as distinguishing characteristics of this class of vaccines. agents for patients who develop progressive disease on standard first-line therapy with PD-1 inhibitors.

However, he added that due to the nature of the agent, which relies on a herpes simplex virus type 1 backbone, its administration will likely remain within the confines of academic centers, which are better equipped to handle the virus.

In our exclusive interview, Milhem discussed the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial (NCT03767348) for patients with solid tumors, as well as in the parallel ARTACUS (NCT04349436) and CERPASS (NCT04050436) studies, which further explore the agent.

Check back on Mondays and Thursdays for exclusive interviews with leading experts in the field of oncology. For more oncology updates, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also present on social networks. On Twitter, follow us on @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive on the air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms*, to receive a notification whenever a new episode is released. While you’re at it, please take a moment to rate us!

Thanks again for listening OncLive on the air®.

*OncLive on the air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic and TuneIn.

Comments are closed.